High coffee consumption was associated with a lower risk for increased liver stiffness (a proxy for fibrosis) but not with steatosis, according to researchers at the University of… read more.
Artificial intelligence (AI) will fundamentally change medicine and healthcare: Diagnostic patient data, e.g. from ECG, EEG or X-ray images, can be analyzed with the help of machine learning,… read more.
Customers quickly identified new applications for the DrugLog device and this led to the development of two new products – WasteLog and PrepLog. Pharmacolog AB CEO Mats Högberg… read more.
Investigations carried out at the La Jolla institute for Immunology (LJI) Show that the combination of vitamin C and TET proteins are essential for the proper function of… read more.
Over the last few decades, neurodegenerative diseases became one of the top 10 global causes of death. Researchers worldwide are making a strong effort to understand neurodegenerative diseases… read more.
Four million UK patients could benefit annually from genetic testing before being prescribed common medicines, according to new research from the University of East Anglia (UEA) in collaboration… read more.
Scientists at Trinity College Dublin announced a significant advance in our understanding of an early onset form of dementia that may also progress our understanding of conditions such… read more.
The migraine treatment rimegepant also appears to have efficacy in preventing migraines, researchers reported on Dec. 15, 2020 in The Lancet.
Article by Christine Clark and Peter Mas-Mollinedo Interview by Peter Mas-Mollinedo Testing of hospital laboratory staff for antibodies to covid-19 revealed some interesting findings and led to questions… read more.
Article by Christine Clark and Peter Mas-Mollinedo Interview by Peter Mas-Mollinedo People often ask if there a case for using both the molecular test and the antigen test.
Understanding what the different tests mean and how they can be used most appropriately underpins the test and trace process.
CymaBay Therapeutics announced that the FDA lifted clinical holds on seladelpar for all three Investigational New Drug (IND) Applications in Nonalcoholic Steatohepatitis (NASH), Primary Biliary Cholangitis (PBC) and… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
